Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Zealand Pharma Yönetim

Yönetim kriter kontrolleri 3/4

Zealand Pharma's CEO'su Adam Steensberg, Mar2022 tarihinde atandı, in görev süresi 2.58 yıldır. in toplam yıllık tazminatı DKK 24.84M olup, şirket hissesi ve opsiyonları dahil olmak üzere 23.2% maaş ve 76.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.048% ine doğrudan sahiptir ve bu hisseler DKK 27.55M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 9.5 yıldır.

Anahtar bilgiler

Adam Steensberg

İcra Kurulu Başkanı

DKK 24.8m

Toplam tazminat

CEO maaş yüzdesi	23.2%
CEO görev süresi	2.6yrs
CEO sahipliği	0.05%
Yönetim ortalama görev süresi	3.1yrs
Yönetim Kurulu ortalama görev süresi	9.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Adam Steensberg'un ücretlendirmesi Zealand Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-DKK 712m
Mar 31 2024	n/a	n/a	-DKK 739m
Dec 31 2023	DKK 25m	DKK 6m	-DKK 704m
Sep 30 2023	n/a	n/a	-DKK 760m
Jun 30 2023	n/a	n/a	-DKK 986m
Mar 31 2023	n/a	n/a	-DKK 1b
Dec 31 2022	DKK 19m	DKK 4m	-DKK 966m
Sep 30 2022	n/a	n/a	-DKK 855m
Jun 30 2022	n/a	n/a	-DKK 845m
Mar 31 2022	n/a	n/a	-DKK 608m
Dec 31 2021	DKK 10m	DKK 3m	-DKK 755m
Sep 30 2021	n/a	n/a	-DKK 925m
Jun 30 2021	n/a	n/a	-DKK 1b
Mar 31 2021	n/a	n/a	-DKK 909m
Dec 31 2020	DKK 7m	DKK 3m	-DKK 669m
Sep 30 2020	n/a	n/a	-DKK 660m
Jun 30 2020	n/a	n/a	-DKK 545m
Mar 31 2020	n/a	n/a	-DKK 624m
Dec 31 2019	DKK 7m	DKK 3m	-DKK 572m

Tazminat ve Piyasa: Adam 'ın toplam tazminatı ($USD 3.68M ) UK pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 3.65M ).

Tazminat ve Kazançlar: Adam şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Adam Steensberg (50 yo)

2.6yrs

Görev süresi

DKK 24,837,000

Tazminat

Mr. Adam Sinding Steensberg, M.D., serves as President and Chief Executive Officer at Zealand Pharma A/S since March 30, 2022. He had been an Executive Vice President of Research & Development and Chief Me...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Adam Steensberg	President & CEO	2.6yrs	DKK 24.84m	0.048% DKK 27.4m
Henriette Wennicke	EVP & CFO	1.9yrs	DKK 9.24m	0.0048% DKK 2.8m
Ivan Moller	Executive VP & COO	6.6yrs	Veri yok	0.064% DKK 36.5m
David Kendall	Chief Medical Officer and Head of R&D	no data	Veri yok	0.013% DKK 7.5m
Mads Kronborg	Head of Investor Relations & Communication	4.2yrs	Veri yok	Veri yok
Ravinder Chahil	EVP & General Counsel	2.8yrs	Veri yok	0.010% DKK 5.9m
Christina Bredal	Executive VP & Chief People Officer	3.5yrs	Veri yok	0.0095% DKK 5.4m
Jens Mikkelsen	Head of Molecular Pharmacology	no data	Veri yok	Veri yok
Danilo Verge	Head of Global Medical Affairs	4.1yrs	Veri yok	Veri yok
Lykke Romer	VP & Head of Finance and Accounting	no data	Veri yok	Veri yok
Eric Cox	Chief Commercial Officer	less than a year	Veri yok	Veri yok
Miriam Katz	Assistant Secretary	no data	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: 0NZU 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Leonard Kruimer	Independent Director	5.5yrs	DKK 764.00k	0.022% DKK 12.3m
Alf Gunnar Nicklasson	Independent Chairman of the Board	9.5yrs	DKK 1.07m	0.026% DKK 14.9m
Kirsten Drejer	Independent Vice Chairman	6.5yrs	DKK 583.00k	0.012% DKK 7.1m
Ake Lernmark	Member of Advisory Board	12.9yrs	Veri yok	Veri yok
Gudmund Korsgard	Board Observer	no data	Veri yok	Veri yok
Jeffrey Berkowitz	Independent Director	5.5yrs	DKK 583.00k	0.012% DKK 6.6m
Bernard Charbonnel	Member of Advisory Board	12.9yrs	Veri yok	Veri yok
Richard Pratley	Member of Advisory Board	12.9yrs	Veri yok	Veri yok
Paul Dorian	Member of Advisory Board	12.9yrs	Veri yok	Veri yok
Gert Van Assche	Member of Advisory Board	12.9yrs	Veri yok	Veri yok
Bernadette Connaughton	Independent Director	5.5yrs	DKK 583.00k	0.012% DKK 6.8m
Anneline Nansen	Employee Representative Director	3.1yrs	DKK 281.00k	0.0021% DKK 1.2m

9.5yrs

Ortalama Görev Süresi

66.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0NZU 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.5 yıldır).

Zealand Pharma Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

President & CEO recently sold kr.31m worth of stock

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Recent updates

Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism

Insufficient new directors

President & CEO recently sold kr.31m worth of stock

Second quarter 2024 earnings released: kr.4.67 loss per share (vs kr.5.50 loss in 2Q 2023)

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide

Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL

Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings released: kr.4.19 loss per share (vs kr.5.77 loss in 1Q 2021)

Insufficient new directors

Zealand Pharma Announces CEO Changes

Full year 2021 earnings: Revenues in line with analyst expectations

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Employee Elected Director Gertrud Rasmussen has left the company

Employee Elected Director Gertrud Rasmussen has left the company

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection

First quarter 2021 earnings released: kr.5.78 loss per share (vs kr.4.98 loss in 1Q 2020)

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes

Full year 2020 earnings released: kr.22.07 loss per share (vs kr.16.91 loss in FY 2019)

Revenue misses expectations

New 90-day low: kr.192

New 90-day low: kr.202

Zealand Pharma A/S Announces Data from the First Phase 3-Trial with Dasiglucagon in Congenital Hyperinsulinism (Chi)

Zealand Pharma A/S to Report Q3, 2021 Results on Nov 11, 2021

Third quarter 2020 earnings released: kr.5.76 loss per share

Revenue misses expectations

Zealand Pharma Continues to Advance Clinical Programs and Commercial Launch Capabilities

New 90-day low: kr.211

New 90-day high: kr.245

Zealand Pharma A/S (CPSE:ZEAL) completed the acquisition of substantially all assets of Valeritas Holdings, Inc.

New 90-day low - kr.220

CEO Tazminat Analizi

CEO